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Abstract: Rabies is a highly fatal zoonotic disease which is primarily caused by rabies virus (RABV)
although other members of the genus Lyssavirus can cause rabies as well. As yet, 14 serologically and
genetically diverse lyssaviruses have been identified, mostly in bats. To assess the quality of rabies
vaccines and immunoglobulin preparations, virus neutralization tests with live RABV are performed
in accordance with enhanced biosafety standards. In the present work, a novel neutralization test
is presented which takes advantage of a modified vesicular stomatitis virus (VSV) from which the
glycoprotein G gene has been deleted and replaced by reporter genes. This single-cycle virus was
trans-complemented with RABV envelope glycoprotein. Neutralization of this pseudotype virus
with RABV reference serum or immune sera from vaccinated mice showed a strong correlation with
the rapid fluorescent focus inhibition test (RFFIT). Importantly, pseudotype viruses containing the
envelope glycoproteins of other lyssaviruses were neutralized by reference serum to a significantly
lesser extent or were not neutralized at all. Taken together, a pseudotype virus system has been
successfully developed which allows the safe, fast, and sensitive detection of neutralizing antibodies
directed against different lyssaviruses.
Keywords: virus neutralization; pseudotype virus; rabies virus; luciferase; biosafety; vaccine;
immunoglobulin
1. Introduction
Rabies is a fatal neurological disorder in humans and other mammalian species which is caused by
rabies virus (RABV), the prototype member of the genus Lyssavirus within the family Rhabdoviridae [1].
The Lyssavirus genus currently contains 14 classified and one proposed species which are classified
into distinct phylogenetic groups [2–8]. Group 1 consists of RABV, Khujand virus (KHUV), Australian
bat lyssavirus (ABLV), European bat lyssavirus type 1 (EBLV-1), European bat lyssavirus type 2
(EBLV-2), Bokeloh bat lyssavirus (BBLV), Aravan virus (ARAV), Duvenhage virus (DUVV), and Irkut
virus (IRKV). Shimoni bat virus (SHIBV), Lagos bat virus (LBV), as well as Mokola virus (MOKV)
represent group 2, while West Caucasian bat virus (WCBV) represents group 3 [5,6]. For Ikoma and
Lleida bat lyssaviruses (IKOV and LLEBV, respectively) the establishment of a novel group 4 has been
proposed [7,8].
The prototype RABV has a worldwide distribution and is found primarily in carnivores (e.g., dogs,
foxes, raccoons, skunks, wolves, etc.) and North American (but not European) bats. Except MOKV,
which has been found in shrews and cats, all other lyssaviruses have their natural reservoir in bats.
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By far, most human cases of rabies are caused by RABV, but sporadic infection with other Lyssavirus
species has been reported to cause the disease as well [9–12].
RABV is usually transmitted to humans through saliva following a bite from an infected
animal. The virus migrates to the central nervous system (CNS) via axonal retrograde transport
and trans-synaptic transmission. Depending on the site of inoculation and the viral load in the
inoculum this can take several weeks during which symptoms are not apparent. Usually, anti-RABV
antibodies cannot be detected during this incubation period, thus impeding early serological diagnosis.
Once the virus has reached the CNS, the outcome of the infection is almost always fatal [13].
Inactivated rabies vaccines have been approved for immunoprophylaxis of animals as well as
humans who are at risk of exposure to RABV (e.g., veterinarians, laboratory workers). The vaccine
provides protection by inducing virus-neutralizing antibodies directed to the single viral envelope
glycoprotein G [14]. Thanks to the obligatory vaccination of pet dogs and cats and campaigns for
vaccination of wildlife, some European countries are now declared rabies-free. The RABV vaccine
protects against infection with members of phylogroup 1, but not of phylogroup 2 [15].
A post-exposure prophylaxis is available as well and includes administration of immunoglobulins
from vaccinated humans or horses and accompanying active immunization with the inactivated RABV
vaccine. This therapy is effective in preventing rabies disease only if given immediately after exposure
to the virus. About 15 million people receive this post-exposure treatment every year following
potential exposure to RABV. Despite being preventable by pre- and post-exposure prophylaxis, RABV
still causes about 50,000 human deaths per year, mostly in India, China, and African countries [16].
This is mainly due to the low availability and accessibility of vaccines and immunoglobulin therapy in
these countries, but also because RABV is not effectively controlled in stray dogs [17].
In order to assess the quality of immunoglobulin preparations, as well as the immune status of
vaccinated animals and humans, a RABV neutralization test is usually performed. The fluorescent
antibody virus neutralization (FAVN) test and the rapid fluorescent focus inhibition test (RFFIT) are
the currently approved methods for the quantification of neutralizing antibodies [18,19]. Both require
handling of live virus, making use of appropriate biosafety containment as well as vaccination of
laboratory personnel necessary [20]. Recently, an alternative virus neutralization assay has been
developed which is based on lentiviral pseudotypes [21].
Vesicular stomatitis virus (VSV), like RABV, is a member of the family Rhabdoviridae, but has
been classified into the genus Vesiculovirus. In the present work, a glycoprotein-G-deficient VSV
expressing two different reporter genes was pseudotyped with lyssavirus envelope proteins using
stably transfected helper cell lines. The VSV pseudotype particles and reporter gene expression were
employed for virus neutralization tests using immune sera from vaccinated animals, World Health
Organization (WHO) reference serum, and neutralizing antibodies. Specificity, sensitivity, and time
requirements of this new pseudotype neutralization test were determined and compared with those of
a commonly used RFFIT test.
2. Materials and Methods
2.1. Cells
Vero cells (C1008) were purchased from the American Type Culture Collection (Manassas,
VA, USA) and maintained in Glasgow’s minimal essential medium (GMEM; Life Technologies,
Zug, Switzerland) supplemented with 5% fetal bovine serum (FBS). Baby Hamster Kidney
(BHK)-G43, a transgenic BHK-21 cell clone expressing the VSV G protein in a regulated manner [22],
was maintained in minimal essential medium (MEM) containing 5% FBS. T-Rex™-Chinese Hamster
Ovary (CHO) cells were purchased from Life Technologies and maintained in Ham’s F12 medium
(Sigma-Aldrich, Buchs, Switzerland) supplemented with 5% FBS.
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2.2. Generation of Helper Cell Lines
For the generation of transgenic helper cell lines, cDNA encoding the following viral envelope
proteins was used: VSV (serotype Indiana) G protein (GenBank accession number: J02428), rabies
challenge virus standard 11 (CVS-11) G protein (GenBank accession number: EU126641) [23],
RABV vaccine strain Street-Alabama-Dufferin B19 (SAD B19) G protein (GenBank accession
number: M31046) [24], European bat lyssavirus 1 (EBLV-1) G protein (GenBank accession number:
EF157976) [25], and Mokola virus (MOKV, strain Ethiopia 16) G protein (GenBank accession number:
U17064) [26]. A codon-optimized cDNA encoding the G protein of European bat lyssavirus 2 (EBLV-2,
isolate RV1787) (GenBank accession number: EU352769) was purchased from GenScript (Piscataway,
NJ, USA). The cDNAs were amplified by PCR and inserted into the pcDNA™ 4/TO/Myc-His
plasmid (Life Technologies) downstream of the cytomegalovirus (CMV) promoter and tetracycline
operator sites. T-Rex™-CHO cells were transfected with recombinant plasmid and Lipofectamine 2000
(Life Technologies). The cells were grown for two weeks with medium containing 1 mg/mL zeocin
(Invivogen, Toulouse, France) and 5 µg/mL blasticidin (Invivogen). Surviving cells were subsequently
cloned by limiting dilution.
2.3. Antibodies and Immune Sera
A monoclonal antibody directed to the RABV G protein (hybridoma clone 16DB4) was provided by
the Swiss Rabies Centre (Bern, Switzerland). The second international standard for human anti-RABV
immunoglobulin (reference serum) was obtained from the National Institute for Biological Standards
and Control (NIBSC, Potters Bar, U.K.), and reconstituted in water to give a final concentration of
2 IU/mL.
Serum samples were obtained from mice (NMRI strain), which had been vaccinated twice
(one week apart) with 0.5 mL of WHO standard RABV vaccine (Sixth International Standard for
Rabies vaccine, 8 IU/mL, NIBSC). Three different vaccine doses (1/10; 1/50; 1/250) were used and
applied to the animals (group size n = 10) via the intraperitoneal route. Two weeks after the second
immunization the animals were bled and sera prepared. The mouse immunization experiments were
approved by the regional council in Darmstadt (authorization number V54-19c20/15-F107/104) and
performed at the Paul-Ehrlich-Institute in Langen, Germany, in compliance with German animal
protection law.
For generation of polyclonal antibodies directed against the G proteins of MOKV and
CVS-11, recombinant vector vaccines based on propagation-incompetent VSV were produced [27].
The ectodomains of the glycoproteins (amino acids 1–439 for CVS-11 G and 1–448 for MOKV G) were
genetically fused to the GCN4_pII trimerization domain and inserted into the fourth transcription
unit of the pVSV*∆G(HA) plasmid [27] resulting in pVSV*∆G(secMOKV-G) and pVSV*∆G(secCVS-G).
The recombinant viruses were generated and propagated in BHK-G43 helper cells as described
previously [28]. Two rabbits were immunized intramuscularly (i.m.) with 108 focus-forming units
(f.f.u.) of either VSV*∆G(secMOKV-G) or VSV*∆G(secCVS-G) in the absence of adjuvant. The immune
response of the animals was boosted using the same vaccine four weeks after the primary immunization.
After four more weeks, the animals were boosted a second time by intramuscular injection of 20 µg
of pCAGGS plasmid DNA encoding the G proteins of CVS-11 and MOKV, respectively. The DNA
was formulated with 20 µL of Lipofectamine®2000 (Life Technologies). The animals were euthanized
and bled four weeks after the final immunization. These animal experiments were performed in
compliance with the Swiss animal protection law and approved by the animal welfare committee of
the canton of Bern (authorization number BE119/13).
2.4. Immunofluorescence Analysis
Transgenic T-Rex™-CHO cell lines were cultured for 24 h on 12 mm glass coverslips with Ham’s
F12 medium containing 5% FBS and 2 µg/mL of doxycycline (Sigma-Aldrich). Control cells received
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medium without doxycycline. The cells were washed with phosphate-buffered saline (PBS) and
incubated with primary antibodies for 60 min on ice. For detection of the G proteins of CVS-11, SAD
B19, EBLV-1, and EBLV-2, cell culture supernatant from hybridoma clone 16DB4 was used (1:200),
while the G protein of MOKV was detected with the polyclonal anti-MOKV-G immune serum (1:500)
produced in rabbits. The cells were washed three times with PBS (4 ◦C) and then fixed for 30 min at
room temperature with 3% paraformaldehyde (AppliChem, Darmstadt, Germany). The cells were
washed twice with PBS containing 0.1 M glycine (AppliChem) and once with PBS and subsequently
incubated with goat anti-mouse IgG AlexaFluor-488 conjugate (1:400, Life Technologies) and goat
anti-rabbit IgG AlexaFluor4-88 conjugate (1:400, Life Technologies), each for 1 h at room temperature.
Finally, the cells were washed twice with PBS and once with distilled water and embedded in Mowiol
4-88 (Sigma) mounting medium.
2.5. Cell Surface Biotinylation
Transgenic T-Rex™-CHO cell lines were seeded in 6-well culture plates (500,000 cells/well) and
cultured for 24 h at 37 ◦C with either normal medium or medium containing 2 µg/mL doxycycline.
The cells were washed three times with ice-cold PBS and incubated for 40 min on ice with 0.5 mg/mL
of Sulfo-NHS-LC-Biotin (Life Technologies). The labeling reaction was stopped by washing the cells
once with PBS containing 0.1 M glycine and incubating them in the same solution for 15 min at 4 ◦C.
Subsequently, the cells were lysed in 1 mL of Nonidet P-40 lysis buffer (50 mM Tris/HCl, pH 7.5,
150 mM NaCl, 0.5% sodium deoxycholate (Sigma-Aldrich), 1% Nonidet P-40 (Sigma-Aldrich), protease
inhibitor cocktail (Sigma-Aldrich, P8340). Thereafter, insoluble material was removed by centrifugation
(20,000× g, 30 min, 4◦C). Clarified cell lysate (10 µL) was mixed with 10 µL of 2× sodium dodecyl
sulfate (SDS; Sigma-Aldrich) sample buffer containing 10% (v/v) 2-mercaptoethanol (Sigma-Aldrich),
heated for 5 min at 90 ◦C, separated by SDS 10% polyacrylamide gel electrophoresis, and transferred
to Porablot 0.45 µm pore size nitrocellulose membranes (Macherey-Nagel, Oensingen, Switzerland)
by semidry blotting (0.8 mA/cm2, 60 min). The membrane was incubated overnight with blocking
reagent (LI-COR Biosciences, Bad Homburg, Germany), washed three times with PBS containing 0.1%
Tween 20 (AppliChem), and subsequently incubated for 60 min with IRDye® 800CW streptavidin
(1:2000; LI-COR Biosciences). The nitrocellulose membrane was washed three times with PBS/0.1%
Tween 20 and once with detergent-free PBS. The biotinylated proteins were detected using the Odyssey
Infrared Imaging System (LI-COR Biosciences).
2.6. Generation of Pseudotype Virus
VSV*∆G(FLuc), a G-deficient VSV-encoding green fluorescent protein (GFP) and firefly luciferase
(FLuc), has been described previously [28]. For generation of a corresponding virus encoding
secreted Nano luciferase (sNLuc), the sNLuc gene was amplified from the pNL1.3 plasmid (Promega,
Dübendorf, Switzerland) and inserted into the XhoI and NheI endonuclease restriction sites of
the pVSV*∆G(Luc) genomic plasmid thereby replacing the firefly luciferase gene. Recombinant
VSV*∆G(sNLuc) was rescued on BHK-G43 helper cells following transfection of cDNA as described
previously [28]. VSV*∆G(FLuc) and VSV*∆G(sNLuc) were propagated on transgenic T-Rex™-CHO
cells in the presence of doxycycline (2 µg/mL). The trans-complemented particles were stored at
−70 ◦C in the presence of 5% FBS. Pseudotype viruses were titrated on Vero cells in 96-well cell
culture plates as described previously [28]. The virus titers were expressed as focus-forming units
per mL (f.f.u./mL). Pseudotype viruses were passaged 3–4 times on helper cells before used in virus
neutralization assays.
2.7. Virus Neutralization Tests
Unless otherwise indicated, immune sera were heated to 56 ◦C for 30 min in order to inactivate
complement factors. The RABV neutralization activity of sera from vaccinated mice was determined
using the modified RFFIT test as described previously [29,30]. For the pseudotype virus neutralization
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(PVN) test, two-fold serial dilutions of the immune sera or mAb 16DB4 were prepared in GMEM
cell culture medium containing 5% FBS. The diluted sera were added to 96-well cell culture plates
(50 µL/well, quadruplicates for each dilution) and incubated for 60 min at 37 ◦C with pseudotype
virus (50 µL/well containing 100 f.f.u.). Vero cell suspension was added to the wells (100,000 cells/mL,
100 µL/well) and incubated at 37 ◦C for at least 8 h. Infection was monitored by fluorescence
microscopy taking advantage of the GFP reporter protein. For each serum dilution, four wells were
scored for the absence or presence of GFP-expressing cells (protected or non-protected wells) and
neutralization doses 50% (ND50) were calculated according to the Spearman-Kärber method [31].
The PVN test was also performed with VSV*∆G(sNLuc) pseudotype viruses. Following
incubation with serially diluted immune sera, the pseudotype virus/immune serum mixture (100 µL)
was added to confluent Vero cells grown in 96-well microtiter plates and incubated for 60 min at 37 ◦C.
The cells were washed twice with GMEM medium and subsequently incubated with 100 µL GMEM
medium per well. At 6 h post-infection, 25 µL of cell culture medium was transferred to a white 96-well
microtiter plate and Nano-Glo luciferase substrate (Promega) was added to each well (25 µL/well).
Luminescence was recorded for 1 s with a Centro LB 960 luminometer (Berthold Technologies, Bad
Wildbad, Germany). If the luminescence signal crossed the threshold value of 200 relative light units
(RLU), the cell population in the well was regarded as infected, while below this value the cells were
considered as negative. ND50 values were calculated according to Spearman and Kärber [31].
2.8. Statistical Analysis
Mean values and standard deviations were calculated. Data were analyzed by Mann-Whitney
and Wilcoxon tests and p < 0.05 was considered significant.
3. Results
3.1. Generation of Transgenic Helper Cell Lines
It has been previously shown that VSV lacking the glycoprotein G (VSV∆G) can be efficiently
trans-complemented with the VSV G protein using a transgenic cell line [22]. This cell line was
engineered to express the VSV G protein in a conditional manner in order to accommodate the
cytotoxic properties of the protein [32]. Here, a similar approach was used for pseudotyping
of VSV∆G with lyssavirus envelope glycoproteins. T-Rex™-CHO cells were transfected with the
pcDNA™ 4/TO/Myc-His plasmid vector encoding the G protein of either VSV (serotype Indiana),
rabies challenge virus standard 11 (CSV-11), rabies virus vaccine strain Street-Alabama-Dufferin
B19 (SAD-B19), EBLV-1, EBLV-2, or MOKV (strain Ethiopia-16). The cells were selected with
the antibiotics zeocin and blasticidin and subsequently cloned by limiting dilution. Following
induction of transgene expression by doxycycline, cell clones were selected for their ability to support
propagation of a recombinant G-deleted VSV expressing GFP (VSV*∆G). The expression of the viral
envelope glycoproteins by the selected cell clones was investigated by indirect immunofluorescence
(Figure 1a). All G proteins could be detected only if the cells had been treated before with doxycycline.
The antibodies reacted with intact, non-permeabilized cells indicating that the G proteins were
expressed at the cell surface. Western blot analysis revealed that the G proteins had the expected
molecular mass (Figure 1b). Using this approach, very little expression of G proteins was observed in
non-induced cells.
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Figure 1. Conditional expression of rhabdoviral G proteins by transgenic helper cell lines.
T-Rex™-Chinese Hamster Ovary (CHO) cells were stably transfected with recombinant pcDNA™
4/TO plasmid encoding the indicated envelope G protein gene, selected with antibiotics, and cloned
by limiting dilution. The cell clones were treated for 8 h with doxycycline (DOX) and inoculated with
vesicular stomatitis virus (VSV)*∆G. Clones that supported replication were selected and analyzed for
expression of G protein: (a) Cell surface expression of the envelope G proteins was detected by indirect
immunofluorescence using mAb I1 (VSV G protein), mAb 16DB4 (for detection of the G proteins of
rabies virus (RABV), European bat lyssavirus type 1 (EBLV-1), and European bat lyssavirus type 2
(EBLV-2)), and rabbit anti-MOKV (Mokola virus) G protein serum as primary reagents; (b) Analysis
of G protein xpression by Weste n lot. Selected cell clones were treated with DOX for 8 h or
left untreated, l beled with a membrane-impermeable bioti ylation reagent, and lysed with NP-40
buffer. Solubilized cell lar proteins were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions and blotted onto a nitrocellulose membrane.
After incubating the membrane with a streptavidin-IRDye800 conjugate, the biotinylated cell surface
proteins were detected with an Odyssey infrared scanner.
3.2. Generation of VSV Pseudotypes
For pseudotyping of VSV with rhabdoviral glycoproteins, either recombinant VSV*∆G(FLuc)
expressing the two reporter genes GFP and FLuc [28] or VSV*∆G(sNLuc) expressing GFP and
secreted sNLuc was used. In order to assess the efficacy of pseudotype particle production, the
T-Rex™-CHO(SAD-G) helper cell line was infected with VSV*∆G(FLuc) using a multiplicity of infection
(m.o.i.) of 0.05 infectious particles per cell. Aliquots of cell culture supernatants were collected at 12, 24,
36, 48, and 60 h post infection (p.i.) and infectious titers determined on Vero cells. Doxycycline-treated
T-Rex™-CHO(SAD-G) cells produced maximum titers of about 108 fluorescent focus-forming units/mL
(f.f.u./mL) at 48 h p.i., whereas only low amounts of virus (<102 f.f.u./mL) were released in the absence
of doxycycline (Figure 2a). To determine the yield of pseudotype virus on different helper cell lines,
the cells were infected with VSV*∆G(FLuc) or VSV*∆G(sNLuc) using an m.o.i. of 0.05. Cell culture
supernatants were collected at 36 h p.i. and infectious virus titers determined on Vero cells. As expected,
the highest virus yield (>108 f.f.u./mL) was obtained with T-Rex™-CHO(VSV-G) cells (Figure 2b).
The pseudotype virus titers achieved on helper cell lines expressing lyssavirus G proteins ranged from
107 to 108 f.f.u./mL. However, T-Rex™-CHO(CVS11-G) cells produced significantly lower pseudotype
virus titers (about 106 f.f.u./mL). This might be attributed to the pronounced neurotropism of CVS-11
and possibly lower expressio levels of appropriate receptors in CHO cells. On all helper cell lines,
infecti us titers of VSV*∆G(FLuc) and VSV*∆G(sNLuc) did not differ (Figure 2b) Of note, significant
levels of infectious pseudotype virus were only produced in the re ence of doxycycline, indicating
that the viruses were not able to propagate in the absence of G protein. Accordingly, non-helper cells
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(e.g., Vero cells) did not release any progeny virus following infection with any of the pseudotype
viruses (data not shown).
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Figure 2. Conditional replication of VSV pseudotypes on helper cell lines. (a) The helper cell
line expressing the G protein of Street-Alabama-Dufferin B19 (SAD B19) as treated for 8 h with
doxycycline (DOX; filled symbols) or were left untreated (open symbols). Following infection of the
cells with VSV*∆G(FLuc) (multiplicity of infection (m.o.i.) of 0.05), cell culture supernatants were
collected at the indicated times and virus titers determined on Vero cells taking advantage of green
fluorescent protein (GFP) reporter expression; (b) Pseudotype virus yield on induced and non-induced
helper cells. Helper cell lines expressing the G proteins either of VSV, SAD B19, challenge virus
standard 11 (CVS-11), EBLV-1, EBLV-2, or MOKV were treated for 8 h with DOX or were left untreated.
The cells were infected VSV*∆G(FLuc) (dark bars) and VSV*∆G(sNLuc) (grey bars) using an m.o.i. of
0.05. Cell culture supernatants were collected at 36 h post infection (p.i.) and titrated on Vero cells;
(c) Pseudotype viruses were produced on T-Rex™-CHO helper cells expressing the G protein of SAD
B19. Vero cells were infected with either VSV*∆G(FLuc) (black bars) or VSV*∆G(sNLuc) (grey bars)
using the indicated m.o.i. At 6 h p.i., luciferase activity was measured in cell lysates and cell culture
supernatant, respectively; (d) Time kinetics of luciferase reporter expression. Vero cells were infected
with SAD B19 G protein-pseudotyped VSV*∆G(FLuc) (black plots) or VSV*∆G(sNLuc) (grey plots)
using an m.o.i. of 0.01. Luciferase activity was measured at the indicated times in cell lysates and cell
culture supernatants, respectively; (e) Vero cells were grown in 96-well microtiter plates and infected
with VSV*∆G(sNLuc) using m.o.i. ranging from 0.0001 to 0.001. The number of GFP-expressing cells
was enumerated in 95 wells and plotted against the Nano luciferase activity that was secreted into the
cell culture supernatant of the respective wells. The dashed line indicates the luminescence cutoff value
above which the cells of a well were regarded as infected. f.f.u.: focus-forming units; RLU: relative
light units. * p < 0.05.
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Infectious pseudotype virus titers were determined on Vero cells taking advantage of GFP reporter
protein expression. To elucidate how virus dose would correlate with luciferase reporter expression,
Vero cells were infected with SAD G protein-pseudotyped VSV*∆G(FLuc) and VSV*∆G(sNLuc) using
different m.o.i. As expected, the luminescence signals recorded 6 h p.i. were proportionally correlated
with the virus dose used, i.e., a 10-fold higher m.o.i. resulted in an approximately 10-fold higher
luminescence signal (Figure 2c). The secreted Nano luciferase activity produced higher signals than
the firefly luciferase, suggesting that this enzyme represents a more sensitive reporter. To find out
which infection time is minimally required to obtain a significantly high luciferase signal, Vero cells
were infected with SAD G protein-pseudotyped VSV*∆G(FLuc) and VSV*∆G(sNLuc) using an m.o.i.
of 0.01. Luminescence could be detected at significantly high levels as early as 6 h p.i. The sNLuc
reporter always produced significantly higher signals than FLuc (Figure 2d).
In order to correlate the number of infectious pseudotype particles with luciferase reporter
activity, Vero cells grown in 96-well microtiter plates were infected with VSV*∆G(sNLuc) using an m.o.i.
ranging from 0.0001 to 0.001 infectious particles per cell. At 20 h p.i., the number of GFP-expressing cells
was determined for 95 individual wells and correlated with the luciferase activity in the corresponding
cell culture supernatants (Figure 2e). The mean luciferase activity per GFP-positive cell was calculated
to be 572 ± 334 relative light units (RLU)/cell.
3.3. Neutralization of Pseudotype Virus
In order to see whether CVS-11 G protein-pseudotyped VSV*∆G(Luc) would be sensitive to
neutralization by immune sera directed to the RABV G protein, the virus (100 f.f.u.) was incubated for
60 min with either human anti-RABV serum, rabbit anti-VSV serum, or no serum at all. Subsequently, the
pseudotype virus-serum mixtures were incubated with T-Rex™-CHO(VSV-G) or T-Rex™-CHO(SAD-G)
helper cells, either in the presence or absence of doxycycline. At 18 h p.i., GFP expression was visualized
by fluorescence microscopy (Figure 3a). In non-induced helper cells, GFP expression was restricted to
single cells whereas in doxycycline-induced cells, virus was able to propagate, which led to an increased
number of GFP-positive cells, thereby facilitating the detection of non-neutralized virus. Anti-RABV
serum (1:80) completely neutralized CVS-11 G protein-pseudotyped VSV*∆G(FLuc) but had no effect
if the virus had been trans-complemented with VSV G protein. Vice versa, anti-VSV immune serum
(1:100) efficiently neutralized VSV G protein-pseudotyped but not CVS-11 G protein-pseudotyped
VSV*∆G(FLuc), indicating that the trans-complementing envelope glycoprotein specifically determined
the susceptibility of the virus to antibody-mediated neutralization.
To determine the neutralization dose 50% (ND50) of the WHO reference serum with the PVN
test, 100 f.f.u. of CVS-11 G protein-pseudotyped VSV*∆G(sNLuc) were incubated with serial two-fold
dilutions of reference serum and then inoculated with Vero cells. GFP reporter expression was
monitored 8 h p.i., and wells completely devoid of GFP-positive cells were regarded as protected.
The test was run in four parallels and ND50 values calculated according to the Spearman–Kärber
method (Figure 3b). The PVN test was also performed using the sNLuc reporter and a luminescence
cutoff value of 200 (see Figure 2e). If higher sNLuc activity was detected in the culture medium,
the cells in this well were regarded as infected and the virus considered as not neutralized. Using
this luminescence cutoff value, a mean ND50 value of 133 was calculated which corresponded well
with the ND50 value of 134 which was obtained with the GFP read-out of the PVN test (Figure 3b).
However, the serum dilution causing 50% inhibition of sNLuc reporter expression was calculated
to be 1/500 (Figure 3c), suggesting that this read-out may offer a more sensitive way to detect
neutralizing antibodies.
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Figure  3.  Pseudotype  virus  neutralization  (PVN)  test  using  the  GFP  reporter  for  detection. 
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Figure 3. Pseudotype virus neutralization (PVN) test using the GFP reporter for detection. VSV*∆G(FLuc)
was trans-complemented with G protein from either VSV or CVS-11. (a) The trans-complemented viruses
(100 f.f.u.) were incubated for 60 min with either anti-RABV reference serum (2 IU/mL, 1:80), anti-VSV
serum (1:100) or without (w/o) any serum and subsequently inoculated with either T-Rex™-CHO-SAD-G
helper cells (if virus was trans-complemented with VSV G protein) or T-Rex™-CHO-VSV-G helper cells
(if virus was trans-complemented with CVS-11 G protein) in the presence or absence of DOX. Expression
of GFP was visualized 24 h post inoculation by fluorescence microscopy; (b) Comparison of the GFP and
luciferase reporter read-outs. Serial two-fold dilutions of human anti-RABV reference serum (2 IU/mL)
were incubated in quadruplicates for 60 min with 100 focus-forming units (f.f.u.) of VSV*∆G(sNLuc)
that was trans-complemented with the CVS-11 G protein. Vero cells were added to the wells and
incubated at 37 ◦C for 20 h. GFP expression was monitored by fluorescence microscopy. In parallel, the
secreted Nano luciferase (sNLuc) activity was determined in the cell culture supernatant. The luciferase
endpoint titers were calculated according to the method by Spearman–Kärber using a cutoff value of
200 RLU (see Figure 2e). The mean values of 11 independent experiments are shown; (c) The luciferase
data were also used to calculate the serum dilution causing a reduction of luciferase by 50% (red dashed
line). The luminescence recorded following infection of the cells in the absence of antibody was set to
100%. Mean values (n = 11) and standard deviations are shown.
In order to compare the PVN test with a commonly used RABV neutralization test, the assay was
run with immune sera collected from mice that had been immunized with decreasing doses of RABV
vaccine. The ND50 values of these sera were calculated and compared with the ND50 values determined
by the modified RFFIT [29,30]. With both methods, the antibody responses of the immunized mice
were found to depend on the vaccine dose with the highest ND50 values associated with the 1/10
vaccine group and the lowest with the 1/250 vaccine group (Figure 4). No significant differences were
observed between the mean ND50 values calculated with either of the two methods.
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Figure 4. Comparis n of the PVN test with the mo ified rapid fluorescent focus i hibition test
(mRFFIT). Serum samples (not treated at 56 ◦C) from mice immunized with the indicated vaccine doses
were analyzed with either the modified RFFIT or the PVN test. The PVN test was performed with
CVS-11 G protein pseudotyped VSV*∆G(sNLuc) using the GFP reporter read-out. The neutralization
dose 50% (ND50) values for individual animals (represented by different symbols) and the mean values
for each vaccine group (n = 10) are shown.
3.4. Analysis of Pseudotype Viruses Bearing Other Lyssavirus Glycoproteins
Although infection with RABV is the most common cause of rabies disease, infection with other
lyssaviruses has been associated with human fatalities as well [33]. Therefore, the PVN test was
adapted to allow the detection of neutralizing antibodies directed to EBLV-1 and EBLV-2, which belong
to phylogroup 1, and MOKV, which belongs to phylogroup 2. In addition, we compared CVS-11 G
protein-pseudotyped with SAD G protein-pseudotyped VSV*∆G(FLuc) in order to see whether the
antigenic properties of these G proteins differ. The neutralization of all these pseudotype viruses was
tested with WHO reference serum (2 IU/mL), mAb 16DB4 (raised against the SAD vaccine strain),
rabbit anti-CVS-11 G protein, and rabbit anti-MOKV G protein using the GFP reporter for detection of
infected cells (Table 1). The WHO reference serum and mAb 16DB4 neutralized CVS-11 G protein- and
SAD G protein-pseudotyped viruses with similar efficacy, whereas anti-CVS-11 serum neutralized
CVS-11 G protein-pseudotyped virus significantly better than virus trans-complemented with the
SAD G protein. The WHO reference serum, mAb 16DB4, and rabbit anti-CVS-11 serum also showed
neutralizing activity against EBLV-1 or EBLV-2 G protein-pseudotyped VSV*∆G(Luc), however, the
ND50 values were very low. Immune serum raised against MOKV showed neutralizing activity
exclusively against MOKV G protein-pseudotyped virus but not against any of the other pseudotype
viruses tested. Vice versa, none of the other immune sera tested was able to neutralize pseudotype
virus containing the MOKV G protein. These results provide further evidence for the specificity of
the PVN test and also demonstrate that the assay can be easily adopted to allow the detection of
neutralizing antibodies directed to other lyssaviruses.
Table 1. Neutralization of pseudotype viruses by immune sera.
Neutralization Titer (ND50/mL)








α-VSV 1333 <4 <4 <4 <4 <4
α-RABV(RAI) a <4 191 224 19 38 <4
mAb 16DB4 b <4 13,881 8913 3452 5673 <4
α-CVS-11 G c <4 1608 5392 7 19 <4
α-MOKV G c <4 <4 <4 <4 <4 1831
a Human anti-RABV WHO international immunoglobulin standard diluted to 2 IU/mL; b Mouse monoclonal
antibody raised against the RABV SAD B19 vaccine strain; c Rabbit polyclonal antibodies directed against the
G proteins of CVS-11 and MOKV. ND50: neutralization doses 50%; VSV: vesicular stomatitis virus; RABV: rabies
virus; EBLV: European bat lyssavirus; MOKV: Mokola virus; mAb: monoclonal antibody; CVS: challenge
virus standard.
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4. Discussion
The RFFIT and FAVN tests are currently the methods of choice for the detection and quantification
of RABV neutralizing antibodies. Because these assays require the handling of live RABV, appropriate
biosafety measures have to be conducted including vaccination of all laboratory workers and testing
of their anti-RABV serum antibody levels on a regular basis. However, the RABV vaccine does not
provide full protection against lyssaviruses other than RABV, in particular viruses of phylogroup 2 are
not recognized by anti-RABV antibodies [15]. The RFFIT test is rather time-consuming because cells
have to be incubated for 24 h prior to detection of infected cells by direct immunofluorescence [30].
Recombinant RABV expressing GFP may facilitate detection of infected cells [34–36], but still is
a hazardous pathogen. Pseudotyping of G-deficient, non-replicative RABV is also feasible but suffers
from slower reporter gene expression [37].
In the present work, virus-neutralizing antibodies were detected taking advantage of
propagation-incompetent pseudotype virus particles that comply with biosafety level 1 or 2 (depending on
the country you are working in). The rapid and strong expression of VSV-encoded reporter genes
(GFP, luciferase) facilitated the detection of virus-infected cells and allowed the assay to be performed
within 8 h (Figure 5). In particular, the luciferase reporter turned out to be highly sensitive and allowed
detection of even a single infected cell. The secreted Nano luciferase turned out to be superior over the firefly
luciferase as it did not require prior lysis of the cells and produced stronger signals. Luminescence was
recorded using a plate reader, which allowed the analysis of several samples in short time. The definition
of a luciferase cutoff value enabled us to discriminate between positive and negative wells and to
calculate ND50 values that were similar to those obtained with the GFP read-out (see Figure 3b). As an
alternative read-out, the half maximal inhibitory serum/antibody concentration (IC50) leading to 50%
reduction of luciferase reporter activity may be calculated. This would allow detection of even lower
levels of neutralizing antibodies, however, the data cannot be directly compared with standard ND50
values. Compared to the conventional RFFIT and FAVN tests, which require a lot of counting of
cells/foci with the risk of individual mistakes by the experimenter, the PVN test with the automated
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The RFITT and FAVN tests require long incubation times in order to allow single non-neutralized
virus to propagate. This is necessary to amplify the otherwise low immunofluorescence signal.
A similar amplification can be achieved for the PVN test if doxycycline-induced helper cells are used
for the assay rather than Vero or BHK-21 cells. On doxycycline-treated helper cells, the virus can
perform two or more replication cycles, which will result in significant amplification of the reporter
signal. Although the sensitivity of the PVN test is enhanced in this way, more time is needed to
perform the assay. In order to avoid any interference of anti-RABV antibodies with the function of
the trans-complementing envelope glycoprotein, it is recommended to use a helper cell line which
expresses a heterologous glycoprotein, e.g., the VSV G protein.
Pseudotyping of VSV has been successfully performed with envelope glycoproteins derived from
diverse viruses, indicating that incorporation of foreign viral glycoproteins into VSV particles occurs
in a rather unspecific manner [38]. Nevertheless, VSV might be particularly well suited for the uptake
and presentation of lyssavirus glycoproteins because VSV belongs to the same virus family and has
the same bullet-shaped morphology as RABV. The envelope of both VSV and RABV is derived from
the plasma membrane where budding takes place and contains a single-type trimeric glycoprotein
of similar size. It is therefore likely that VSV pseudotype particles present lyssavirus glycoproteins
in their proper conformation, similar or identical to the conformation presented by authentic RABV.
This aspect is important since a considerable fraction of virus-neutralizing antibodies may bind to
conformation-dependent epitopes [39,40].
Pseudotype particles can be produced quite easily by propagating VSV*∆G(Luc) or VSV*∆G(sNLuc)
on helper cells expressing the viral glycoprotein of choice, e.g., RABV G protein. We used a conditional
expression system because several viral glycoproteins, e.g., the VSV G protein [32], are known to
exhibit cytotoxic properties which may interfere with any constitutive expression of these glycoproteins.
The trans-complementation of VSV*∆G by helper cells expressing the VSV G protein has never led to
the emergence of propagation-competent VSV since this cell line was used for the first time more than
10 years ago [22]. Probably, the tight association of the VSV nucleocapsid protein with viral genomic
RNA makes any recombination with mRNAs extremely unlikely. The trans-complementation of
G-protein-deleted VSV may also be achieved by transient expression of viral glycoproteins. However,
transfection of cells is laborious and expensive and often results in low and unsteady pseudotype virus
titers. As an alternative to trans-complemented virus particles, chimeric VSV may be produced in which
the VSV G gene is replaced by a foreign viral glycoprotein [38]. However, these propagation-competent
viruses are free to mutate so that it cannot be ruled out that virulent viruses eventually evolve.
5. Conclusions
In conclusion, a safe, sensitive and reliable pseudotype virus neutralization test has been
developed which allows rapid and sensitive quantification of antibodies with neutralizing activity
against RABV and other lyssaviruses.
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